JP5284953B2 - 硝子体内注入用のプロドラッグ - Google Patents
硝子体内注入用のプロドラッグ Download PDFInfo
- Publication number
- JP5284953B2 JP5284953B2 JP2009512617A JP2009512617A JP5284953B2 JP 5284953 B2 JP5284953 B2 JP 5284953B2 JP 2009512617 A JP2009512617 A JP 2009512617A JP 2009512617 A JP2009512617 A JP 2009512617A JP 5284953 B2 JP5284953 B2 JP 5284953B2
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- drug
- growth factor
- vitreous
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
0.8%(8mg/ml)のデキサメタゾンパルミテートエマルジョンを、ウサギの硝子体内に、単回注入により投与した(100L)。動物を、1、7、14、21、28又は60日目に安楽死させた(n=4/時点)。組織中のデキサメタゾン(D)及びデキサメタゾンパルミテート(DP)濃度を測定した。全ての濃度をng/gにおいて表す。
Claims (13)
- 患者における、後眼部に影響を及ぼす眼性疾患の治療用の薬剤の製造への、プロドラッグの使用であって、前記プロドラッグが眼科用薬剤のアルキルエステルであり、前記アルキル基が4以上の炭素原子を含み、前記プロドラッグがエマルジョン中に存在し、前記薬剤が硝子体への注入用に調製され、注入の頻度が、1ヵ月当たり1回以下の注入であり、
前記エマルジョンがヘキサデシルオキシプロピルサイリックシドホビルおよび1−O−ヘキサデシルプロパンジオール−3−ホスホガンシクロビルを含まず、かつ
前記プロドラッグがリン酸エステル及びホスホン酸エステルのいずれも含まない、前記使用。 - 前記プロドラッグの1回の注入の2ヵ月後において、前記薬剤が硝子体において検出されないか、又は前記薬剤に対する前記プロドラッグのモル比が、硝子体において60超である、請求項1記載の使用。
- 前記プロドラッグの1回の注入の2ヵ月後において、前記薬剤に対する前記プロドラッグのモル比が、網膜において60未満である、請求項1記載の使用。
- 前記プロドラッグの1回の注入の2ヵ月後において、前記薬剤に対する前記プロドラッグのモル比が、脈絡膜において60未満である、請求項1記載の使用。
- 前記プロドラッグが、硝子体において前記薬剤の治療的有効量が持続的に放出されることを可能にする量で、少なくとも1ヶ月の期間にわたり注入される、請求項1から4のいずれか1項記載の使用。
- 前記プロドラッグが、2ヵ月に1回以下で注入される、請求項1から5のいずれか1項記載の使用。
- 前記プロドラッグの半減期が少なくとも15日である、請求項1から6のいずれか1項記載の方法。
- 前記プロドラッグがデキサメタゾンパルミテートである、請求項1から7のいずれか1項記載の使用。
- 前記プロドラッグが、眼への使用に適する適切な賦形剤又は担体と組み合わされている、請求項1から8のいずれか1項記載の使用。
- 前記プロドラッグが、以下からなる群から選択される少なくとも1つの薬剤を放出する、請求項1から9のいずれか1項記載の使用:イドクスウリジン、トリフルオロチミジン、トリフルオロウリジン、アシクロビル、ガンシクロビル、シドホビル、インターフェロン、DDI、AZT、フォスカメット、ビダラビン、イルバヴィリンからなる群から選択される抗ウイルス剤、アンフェナク、ケトロラク、インドメタシン、イブプロフェン、ジクロフェナク、フルルビプロフェン、ピロキシカム及び他のCOX2阻害剤からなる群から選択される非ステロイド性抗炎症、サイトカイン、インターロイキン及び成長因子上皮成長因子、線維芽細胞成長因子、色素上皮細胞成長因子、血小板由来成長因子、TGFβ、毛様体神経栄養成長因子、神経膠由来の神経栄養因子、NGF、EPO、PLGF、脳神経成長因子、血管内皮成長因子、及びかかるサイトカイン及び成長因子の活性を阻害するモノクローナル抗体又は蛋白質、アルクロメタゾンジプロピオネート、アムシノニド、アミシナフェル、アムシナフィド、ベクラメタゾン、ベタメタゾン、ジプロピオン酸ベタメタゾン、吉草酸ベタメタゾン、クロベタゾンプロピオネート、クロロプレドニゾン、クロコルテロン、コルチゾル、コーチゾン、コルトドキソン、ジフルオロソンジアセタート、デシノロン、デソニド、デフルプレドネート、ジヒドロキシコーチゾン、デソキシメタゾン、デキサメタゾン、デフラザコート、ジフロラゾン、酢酸ジフロラゾン、ジクロリゾン、ベタメタゾンのエステル、フルアザコルト、フルセトニド、フルクロロニド、フルドロチゾン、フルオロコーチゾン、フルメタゾン、フルニソリド、フルオシノニド、フルオシノロン、フルオシノロンアセトニド、フルコルトロン、フルペロロン、フルプレドニソロン、フルロアンドレノロンアセトニド、フルオシノロンアセトニド、フルランドレノリド、フルオラメトロン、フルチカゾンプロピオネート、ヒドロコルチゾン、酪酸ヒドロコルチゾン、ヒドロコルチゾン吉草酸エステル、ハイドロコルタメート、ロテプレンドール、メドリゾン、メプレドニゾン、メチルプレドニゾン、メチルプレドニゾロン、モメタゾンフロアート、パラメタゾン、酢酸パラメタゾン、プレドニゾン、プレドニゾロン、プレドニドン、トリアムシノロンアセトニド、トリアムシノロンヘキサカトニド及びトリアムシノロン、並びにそれらの塩、誘導体及び混合物、からなる群から選択される抗炎症剤、血管新生阻害剤、ムラミルジペプチド、サイクロスポリン、インターフェロン、インターロイキン2、サイトカイン、タクロリムス、腫瘍壊死因子、ペントスタチン、チモペンチン、形質転換因子β2、エリスロポエチンからなる群から選択される免疫応答調節物質、抗新生蛋白質、抗体又は抗体断片、オリゴアプタマー、アプタマー及び遺伝子断片。
- 後眼部に影響を及ぼす障害の治療又は予防が、後部眼の部位に影響を及ぼすか又は関与するあらゆる疾患、疾病又は症状の治療を含んでなる、請求項1から10のいずれか1項記載の使用。
- 前記障害が、以下のうちの1つ以上である、請求項1から10のいずれか1項記載の使用:黄斑障害、炎症性障害、血管障害、遺伝網膜ジストロフィー、レーザーによって生じる外傷、光力学的治療、光凝固、手術中の低潅流、黄斑穴、腫瘍、後部ブドウ膜の黒色腫、網膜芽腫及び脈絡膜転移と関連する網膜疾患。
- 患者における、後眼部の疾患又は症状の治療期間を延長させる、眼科用組成物の製造へのプロドラッグの使用であって、前記プロドラッグが、眼科用薬剤のアルキルエステルであり、前記アルキル基が4以上の炭素原子を含み、前記プロドラッグがリン酸エステル及びホスホン酸エステルのいずれも含まず、前記プロドラッグが1ヵ月に1回以下で硝子体に注入される、前記使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06290901.5 | 2006-06-01 | ||
EP06290901.5A EP1864667B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
US11/444,337 US20070281914A1 (en) | 2006-06-01 | 2006-06-01 | Use of a steroid prodrug for the treatment of disease of the posterior segment of the eye |
US11/444,349 | 2006-06-01 | ||
EP06290902A EP1864668B1 (en) | 2006-06-01 | 2006-06-01 | Use of prodrugs for ocular intravitreous administration |
US11/444,349 US20070280902A1 (en) | 2006-06-01 | 2006-06-01 | Method for treating eye disease or conditions affecting the posterior segment of the eye |
PCT/EP2007/055414 WO2007138114A1 (en) | 2006-06-01 | 2007-06-01 | Use of prodrugs for ocular intravireous administration |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009538880A JP2009538880A (ja) | 2009-11-12 |
JP5284953B2 true JP5284953B2 (ja) | 2013-09-11 |
Family
ID=39712456
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009512617A Expired - Fee Related JP5284953B2 (ja) | 2006-06-01 | 2007-06-01 | 硝子体内注入用のプロドラッグ |
JP2009512616A Expired - Fee Related JP5455624B2 (ja) | 2006-06-01 | 2007-06-01 | 後眼部の疾患治療用のステロイドプロドラッグの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009512616A Expired - Fee Related JP5455624B2 (ja) | 2006-06-01 | 2007-06-01 | 後眼部の疾患治療用のステロイドプロドラッグの使用 |
Country Status (15)
Country | Link |
---|---|
US (4) | US20070280902A1 (ja) |
EP (4) | EP1864667B1 (ja) |
JP (2) | JP5284953B2 (ja) |
KR (1) | KR101408317B1 (ja) |
CN (1) | CN101553235B (ja) |
AU (1) | AU2007267079B2 (ja) |
CA (1) | CA2653902C (ja) |
DK (2) | DK2319517T3 (ja) |
ES (1) | ES2399976T3 (ja) |
HK (2) | HK1110219A1 (ja) |
IL (1) | IL195626A (ja) |
PL (4) | PL2322183T3 (ja) |
PT (2) | PT1864668E (ja) |
SI (1) | SI1864668T1 (ja) |
WO (2) | WO2007138113A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1864668T1 (sl) | 2006-06-01 | 2013-04-30 | Novagali Pharma S.A. | Uporaba predzdravil za okularno intravitrealno dajanje |
US10463609B2 (en) * | 2007-10-05 | 2019-11-05 | Wayne State University | Dendrimers for sustained release of compounds |
WO2009071594A1 (en) * | 2007-12-04 | 2009-06-11 | Novagali Pharma Sa | Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders |
JP5591226B2 (ja) | 2008-05-12 | 2014-09-17 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | 眼内薬物送達装置および関連する方法 |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
UA111867C2 (uk) * | 2011-11-11 | 2016-06-24 | Аллерган, Інк. | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ |
CN104125830B (zh) * | 2012-02-10 | 2018-01-16 | 台湾微脂体股份有限公司 | 用以减少眼用类固醇的并发症的药物组合物 |
CN110944668A (zh) | 2017-06-16 | 2020-03-31 | 学校法人同志社 | 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用 |
EP3707193A1 (en) | 2017-11-10 | 2020-09-16 | The Johns Hopkins University | Dendrimer delivery system and methods of use thereof |
CN111068071A (zh) * | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
HRP20231000T1 (hr) * | 2020-02-25 | 2023-12-08 | Labomed Pharmaceutical Company S.A. | Oralne otopine koje sadrže fludrokortizon acetat |
WO2022058325A1 (en) | 2020-09-16 | 2022-03-24 | Santen Sas | Oil-in-water emulsions for intravitreal administration |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS609726B2 (ja) | 1980-05-15 | 1985-03-12 | 株式会社 ミドリ十字 | ステロイド製剤 |
JPS5716818A (en) | 1981-04-25 | 1982-01-28 | Green Cross Corp:The | Steroid fatty emulsion |
AU531588B2 (en) | 1981-08-17 | 1983-09-01 | Yoshitomi Pharmaceutical Industries, Ltd. | Emulsifying water-insoluble steroid |
EP0244178A3 (en) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
AU4201189A (en) | 1988-08-26 | 1990-03-23 | Alcon Laboratories, Inc. | Combination of quinolone antibiotics and steroids for topical ophthalmic use |
JPH05132498A (ja) * | 1991-11-08 | 1993-05-28 | Asahi Glass Co Ltd | ステロイド誘導体およびその製剤 |
IL101241A (en) | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
CA2125060C (en) | 1993-07-02 | 1999-03-30 | Henry P. Dabrowski | Ophthalmic solution for artificial tears |
ATE198880T1 (de) * | 1993-08-02 | 2001-02-15 | Commw Scient Ind Res Org | Therapeutische verbindung - fettsäurekonjugate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
JP3410364B2 (ja) | 1997-05-14 | 2003-05-26 | 千寿製薬株式会社 | ジフルプレドナート含有組成物 |
US6114319A (en) | 1997-05-14 | 2000-09-05 | Senju Pharmaceutical Co., Ltd. | Compositions containing difluprednate |
IL121647A (en) * | 1997-08-28 | 2001-07-24 | Pharmateam Dev Ltd | Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate |
EP1020194A4 (en) | 1997-10-01 | 2003-05-21 | Wakamoto Pharma Co Ltd | OIL / WATER EMULSION COMPILATIONS |
JP2000212067A (ja) * | 1999-01-19 | 2000-08-02 | Towa Yakuhin Kk | 薬物含有エマルジョン製剤 |
CN100335036C (zh) | 2001-11-01 | 2007-09-05 | 耶路撒冷希伯来语大学依苏姆研究开发公司 | 用于干眼症治疗的方法和组合物 |
US20040151754A1 (en) * | 2002-12-20 | 2004-08-05 | Control Delivery Systems, Inc. | Steroid suspensions for intraocular use |
US20050009910A1 (en) * | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
SI1663185T1 (sl) * | 2003-09-22 | 2009-04-30 | Onepharm Res & Dev Gmbh | Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti |
US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
DE602004022523D1 (de) * | 2004-07-02 | 2009-09-24 | Novagali Pharma Sa | Verwendung von Emulsionen zur intra- und periocularen Injection |
JP2008505978A (ja) * | 2004-07-12 | 2008-02-28 | アラーガン、インコーポレイテッド | 眼病用組成物および眼病治療法 |
CA2582096C (en) * | 2004-10-01 | 2014-01-07 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
US20060094700A1 (en) * | 2004-11-02 | 2006-05-04 | Allergan, Inc. | Heat sterilization of a steroid in the presence of phosphate |
JP5008571B2 (ja) * | 2004-11-09 | 2012-08-22 | ノバガリ ファルマ エスア | 免疫抑制剤を含む眼科用エマルジョン |
CN1905012A (zh) | 2005-07-31 | 2007-01-31 | 新科实业有限公司 | 具有微驱动器的磁头折片组合及其磁盘驱动装置 |
US8109884B2 (en) | 2005-09-23 | 2012-02-07 | Kitchener Clark Wilson | Dynamic metabolism monitoring system |
SI1864668T1 (sl) | 2006-06-01 | 2013-04-30 | Novagali Pharma S.A. | Uporaba predzdravil za okularno intravitrealno dajanje |
-
2006
- 2006-06-01 SI SI200631521T patent/SI1864668T1/sl unknown
- 2006-06-01 PL PL10177375T patent/PL2322183T3/pl unknown
- 2006-06-01 EP EP06290901.5A patent/EP1864667B1/en active Active
- 2006-06-01 US US11/444,349 patent/US20070280902A1/en not_active Abandoned
- 2006-06-01 ES ES06290902T patent/ES2399976T3/es active Active
- 2006-06-01 DK DK10177382.8T patent/DK2319517T3/da active
- 2006-06-01 EP EP06290902A patent/EP1864668B1/en active Active
- 2006-06-01 US US11/444,337 patent/US20070281914A1/en not_active Abandoned
- 2006-06-01 PL PL10177382T patent/PL2319517T3/pl unknown
- 2006-06-01 EP EP10177382.8A patent/EP2319517B1/en active Active
- 2006-06-01 DK DK06290902.3T patent/DK1864668T3/da active
- 2006-06-01 PT PT62909023T patent/PT1864668E/pt unknown
- 2006-06-01 PL PL06290902T patent/PL1864668T3/pl unknown
- 2006-06-01 PL PL06290901T patent/PL1864667T3/pl unknown
- 2006-06-01 EP EP10177375.2A patent/EP2322183B1/en active Active
- 2006-06-01 PT PT62909015T patent/PT1864667E/pt unknown
-
2007
- 2007-06-01 CA CA2653902A patent/CA2653902C/en not_active Expired - Fee Related
- 2007-06-01 WO PCT/EP2007/055413 patent/WO2007138113A1/en active Application Filing
- 2007-06-01 WO PCT/EP2007/055414 patent/WO2007138114A1/en active Application Filing
- 2007-06-01 AU AU2007267079A patent/AU2007267079B2/en not_active Ceased
- 2007-06-01 CN CN2007800201723A patent/CN101553235B/zh not_active Expired - Fee Related
- 2007-06-01 JP JP2009512617A patent/JP5284953B2/ja not_active Expired - Fee Related
- 2007-06-01 KR KR1020087031197A patent/KR101408317B1/ko active IP Right Grant
- 2007-06-01 US US11/806,554 patent/US8227452B2/en active Active
- 2007-06-01 US US11/806,556 patent/US9192567B2/en not_active Expired - Fee Related
- 2007-06-01 JP JP2009512616A patent/JP5455624B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-21 HK HK08104425.9A patent/HK1110219A1/xx not_active IP Right Cessation
- 2008-04-23 HK HK08104540.9A patent/HK1110221A1/xx not_active IP Right Cessation
- 2008-12-01 IL IL195626A patent/IL195626A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5284953B2 (ja) | 硝子体内注入用のプロドラッグ | |
JP2017014269A (ja) | パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物 | |
ES2522524T3 (es) | Uso de profármacos para la administración intravenosa ocular | |
KR101541416B1 (ko) | 후안부 질환 치료를 위한 스테로이드 전구약물의 용도 | |
ES2437160T3 (es) | Uso de profármacos para la administración intravítrea ocular | |
Biopharma | Lambert et al. | |
JP2007056012A (ja) | 軟膏様組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100517 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130507 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130530 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5284953 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |